EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

Deliang Guo, Robert M. Prins, Julie Dang, Daisuke Kuga, Akio Iwanami, Horacio Soto, Kelly Y. Lin, Tiffany T. Huang, David Akhavan, M. Benjamin Hock, Shaojun Zhu, Ava A. Kofman, Steve J. Bensinger, William H. Yong, Harry V. Vinters, Steve Horvath, Andrew D. Watson, John G. Kuhn, H. Ian Robins, Minesh P. MehtaPatrick Y. Wen, Lisa M. Deangelis, Michael D. Prados, Ingo K. Mellinghoff, Timothy F. Cloughesy, Paul S. Mischel

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Glioblastoma, the most common malignant brain tumor, is among the most lethal and difficult cancers to treat. Although epidermal growth factor receptor (EGFR) mutations are frequent in glioblastoma,their clinical relevance is poorly understood. Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).This response was mediated by Akt; however, clinical data from rapamycin-treated patients showed that SREBP-1 activation was independent of the mammalian target of rapamycin complex 1, possibly explaining rapamycin's poor efficacy in the treatment of such tumors. Glioblastomas without constitutively active EGFR signaling were resistant to inhibition of fatty acid synthesis, whereas introduction of a constitutively active mutant form of EGFR, EGFRvIII, sensitized tumor xenografts in mice to cell death, which was augmented by the hydroxymethylglutaryl coenzyme A reductase inhibitor atorvastatin. These results identify a previously undescribed EGFR-mediated prosurvivalmetabolic pathway and suggest new therapeutic approaches to treating EGFR-activated glioblastomas.

Original languageEnglish
JournalScience Signaling
Volume2
Issue number101
DOIs
Publication statusPublished - 2009 Dec 15
Externally publishedYes

Fingerprint

Sterol Regulatory Element Binding Protein 1
Sirolimus
Glioblastoma
Epidermal Growth Factor Receptor
Tumors
Therapeutics
Neoplasms
Fatty Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cell death
Coenzyme A
Heterografts
Brain Neoplasms
Brain
Oxidoreductases
Cell Death
Chemical activation
Mutation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. / Guo, Deliang; Prins, Robert M.; Dang, Julie; Kuga, Daisuke; Iwanami, Akio; Soto, Horacio; Lin, Kelly Y.; Huang, Tiffany T.; Akhavan, David; Hock, M. Benjamin; Zhu, Shaojun; Kofman, Ava A.; Bensinger, Steve J.; Yong, William H.; Vinters, Harry V.; Horvath, Steve; Watson, Andrew D.; Kuhn, John G.; Robins, H. Ian; Mehta, Minesh P.; Wen, Patrick Y.; Deangelis, Lisa M.; Prados, Michael D.; Mellinghoff, Ingo K.; Cloughesy, Timothy F.; Mischel, Paul S.

In: Science Signaling, Vol. 2, No. 101, 15.12.2009.

Research output: Contribution to journalArticle

Guo, D, Prins, RM, Dang, J, Kuga, D, Iwanami, A, Soto, H, Lin, KY, Huang, TT, Akhavan, D, Hock, MB, Zhu, S, Kofman, AA, Bensinger, SJ, Yong, WH, Vinters, HV, Horvath, S, Watson, AD, Kuhn, JG, Robins, HI, Mehta, MP, Wen, PY, Deangelis, LM, Prados, MD, Mellinghoff, IK, Cloughesy, TF & Mischel, PS 2009, 'EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy', Science Signaling, vol. 2, no. 101. https://doi.org/10.1126/scisignal.2000446
Guo, Deliang ; Prins, Robert M. ; Dang, Julie ; Kuga, Daisuke ; Iwanami, Akio ; Soto, Horacio ; Lin, Kelly Y. ; Huang, Tiffany T. ; Akhavan, David ; Hock, M. Benjamin ; Zhu, Shaojun ; Kofman, Ava A. ; Bensinger, Steve J. ; Yong, William H. ; Vinters, Harry V. ; Horvath, Steve ; Watson, Andrew D. ; Kuhn, John G. ; Robins, H. Ian ; Mehta, Minesh P. ; Wen, Patrick Y. ; Deangelis, Lisa M. ; Prados, Michael D. ; Mellinghoff, Ingo K. ; Cloughesy, Timothy F. ; Mischel, Paul S. / EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. In: Science Signaling. 2009 ; Vol. 2, No. 101.
@article{a7d7c6f2e5c14bbc8450589de89f9fa5,
title = "EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy",
abstract = "Glioblastoma, the most common malignant brain tumor, is among the most lethal and difficult cancers to treat. Although epidermal growth factor receptor (EGFR) mutations are frequent in glioblastoma,their clinical relevance is poorly understood. Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).This response was mediated by Akt; however, clinical data from rapamycin-treated patients showed that SREBP-1 activation was independent of the mammalian target of rapamycin complex 1, possibly explaining rapamycin's poor efficacy in the treatment of such tumors. Glioblastomas without constitutively active EGFR signaling were resistant to inhibition of fatty acid synthesis, whereas introduction of a constitutively active mutant form of EGFR, EGFRvIII, sensitized tumor xenografts in mice to cell death, which was augmented by the hydroxymethylglutaryl coenzyme A reductase inhibitor atorvastatin. These results identify a previously undescribed EGFR-mediated prosurvivalmetabolic pathway and suggest new therapeutic approaches to treating EGFR-activated glioblastomas.",
author = "Deliang Guo and Prins, {Robert M.} and Julie Dang and Daisuke Kuga and Akio Iwanami and Horacio Soto and Lin, {Kelly Y.} and Huang, {Tiffany T.} and David Akhavan and Hock, {M. Benjamin} and Shaojun Zhu and Kofman, {Ava A.} and Bensinger, {Steve J.} and Yong, {William H.} and Vinters, {Harry V.} and Steve Horvath and Watson, {Andrew D.} and Kuhn, {John G.} and Robins, {H. Ian} and Mehta, {Minesh P.} and Wen, {Patrick Y.} and Deangelis, {Lisa M.} and Prados, {Michael D.} and Mellinghoff, {Ingo K.} and Cloughesy, {Timothy F.} and Mischel, {Paul S.}",
year = "2009",
month = "12",
day = "15",
doi = "10.1126/scisignal.2000446",
language = "English",
volume = "2",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "101",

}

TY - JOUR

T1 - EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

AU - Guo, Deliang

AU - Prins, Robert M.

AU - Dang, Julie

AU - Kuga, Daisuke

AU - Iwanami, Akio

AU - Soto, Horacio

AU - Lin, Kelly Y.

AU - Huang, Tiffany T.

AU - Akhavan, David

AU - Hock, M. Benjamin

AU - Zhu, Shaojun

AU - Kofman, Ava A.

AU - Bensinger, Steve J.

AU - Yong, William H.

AU - Vinters, Harry V.

AU - Horvath, Steve

AU - Watson, Andrew D.

AU - Kuhn, John G.

AU - Robins, H. Ian

AU - Mehta, Minesh P.

AU - Wen, Patrick Y.

AU - Deangelis, Lisa M.

AU - Prados, Michael D.

AU - Mellinghoff, Ingo K.

AU - Cloughesy, Timothy F.

AU - Mischel, Paul S.

PY - 2009/12/15

Y1 - 2009/12/15

N2 - Glioblastoma, the most common malignant brain tumor, is among the most lethal and difficult cancers to treat. Although epidermal growth factor receptor (EGFR) mutations are frequent in glioblastoma,their clinical relevance is poorly understood. Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).This response was mediated by Akt; however, clinical data from rapamycin-treated patients showed that SREBP-1 activation was independent of the mammalian target of rapamycin complex 1, possibly explaining rapamycin's poor efficacy in the treatment of such tumors. Glioblastomas without constitutively active EGFR signaling were resistant to inhibition of fatty acid synthesis, whereas introduction of a constitutively active mutant form of EGFR, EGFRvIII, sensitized tumor xenografts in mice to cell death, which was augmented by the hydroxymethylglutaryl coenzyme A reductase inhibitor atorvastatin. These results identify a previously undescribed EGFR-mediated prosurvivalmetabolic pathway and suggest new therapeutic approaches to treating EGFR-activated glioblastomas.

AB - Glioblastoma, the most common malignant brain tumor, is among the most lethal and difficult cancers to treat. Although epidermal growth factor receptor (EGFR) mutations are frequent in glioblastoma,their clinical relevance is poorly understood. Studies of tumors from patients treated with the EGFR inhibitor lapatinib revealed that EGFR induces the cleavage and nuclear translocation of the master transcriptional regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1).This response was mediated by Akt; however, clinical data from rapamycin-treated patients showed that SREBP-1 activation was independent of the mammalian target of rapamycin complex 1, possibly explaining rapamycin's poor efficacy in the treatment of such tumors. Glioblastomas without constitutively active EGFR signaling were resistant to inhibition of fatty acid synthesis, whereas introduction of a constitutively active mutant form of EGFR, EGFRvIII, sensitized tumor xenografts in mice to cell death, which was augmented by the hydroxymethylglutaryl coenzyme A reductase inhibitor atorvastatin. These results identify a previously undescribed EGFR-mediated prosurvivalmetabolic pathway and suggest new therapeutic approaches to treating EGFR-activated glioblastomas.

UR - http://www.scopus.com/inward/record.url?scp=77649216053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649216053&partnerID=8YFLogxK

U2 - 10.1126/scisignal.2000446

DO - 10.1126/scisignal.2000446

M3 - Article

C2 - 20009104

AN - SCOPUS:77649216053

VL - 2

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 101

ER -